Project cooperationUpdated on 8 January 2026
Vascular Biology and Metabolic Regulation in Cardiometabolic Diseases
Head of vascular signaling group at Migal
Kiryat Shmona, Israel
About
I am a principal investigator with extensive expertise in vascular biology and endothelial signaling, with a strong focus on the role of metabolic regulation and lipid-mediated pathways in cardiometabolic and pulmonary vascular diseases. My research addresses fundamental mechanisms of endothelial dysfunction, vascular remodeling, inflammation–metabolism interactions, and endothelial cell plasticity.
My work integrates mechanistic studies with translational approaches, using disease-relevant human endothelial cell models and established preclinical models to investigate signaling pathways, lipid-derived bioactive mediators, and metabolic regulators of vascular function. I contribute to hypothesis-driven experimental design, mechanistic validation, and functional assessment of vascular phenotypes relevant to rare and complex cardiometabolic diseases.
I have strong experience in international collaborative research and EU-aligned consortia. I am interested in Horizon Europe Cluster 1 – Health projects addressing cardiometabolic and rare diseases, with an emphasis on translational strategies that bridge fundamental vascular biology with disease-modifying therapeutic approaches.
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Shira Landau-Levi
Assistant professor at Technion - Israel Institute of Technology at Technion Israel Institute of Technology
Haifa, Israel
Project cooperation
Biotech looking for collaboration partners: Cell therapy and cell-derived products
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Moayed Hamza
CEO & Founder at HAON Life Science
Dublin, Ireland
Project cooperation
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Andriana Margariti
Professor of Vascular and Regenerative Medicine at Queen's University Belfast
BELFAST, United Kingdom